Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacyRebecca Gardner, Michael C. Jensen, Francesco Ceppi et al.|Blood|2019Cited by 287
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trialNicholas A. Vitanza, Michael C. Jensen, Amy Lee et al.|Nature Medicine|2025Cited by 154
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cellsAdam J. Lamble, Nirali N. Shah, Deepa Bhojwani et al.|Blood Advances|2022Cited by 149
Lymphocyte apheresis for chimeric antigen receptor T‐cell manufacturing in children and young adults with leukemia and neuroblastomaFrancesco Ceppi, Rebecca Gardner, Julie Rivers et al.|Transfusion|2018Cited by 93
Beyond the storm — subacute toxicities and late effects in children receiving CAR T cellsHaneen Shalabi, Nirali N. Shah, Juliane Gust et al.|Nature Reviews Clinical Oncology|2021Cited by 69